Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 antibody and decitabine in relapsed or refractory malignancies
NCT02961101Phase 2Recruiting
- Start
- May 2016
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), gastrointestinal cancer and 7 more. Started May 2016; status: recruiting.
02
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)gastrointestinal cancerhepatocellular carcinoma (HCC)breast cancer
Beyond the preview
Go deeper on NCT02961101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961101.